Genetic and Telomere Assessments Improved Pulmonary Fibrosis Care
Integrating genetic and telomere assessments into clinical care helps physicians refine diagnoses and adjust pulmonary fibrosis treatment plans.
Integrating genetic and telomere assessments into clinical care helps physicians refine diagnoses and adjust pulmonary fibrosis treatment plans.
A new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
Researchers linked loss-of-function variants in the TMEM63B gene to a novel disorder causing interstitial lung disease in some pediatric patients.
A study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.
A 28-year-old cystic fibrosis patient underwent a 36-hour quadruple organ transplant for both lungs, a liver, and a kidney from a single donor.
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
New research suggests that microplastic particles can bind to allergens and carry them deeper into the respiratory system.
Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.